Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : ahhaha's ahs -- Ignore unavailable to you. Want to Upgrade?

To: Lhn5 who wrote (23546)	6/17/2013 10:06:32 PM
From: ahhaha	Respond to of 24758

Orphan drug status is reserved for rare diseases. There's not much money in't, so bios only break into such a drug by accident usually. As far as I know ASTX is only working on broad application anti cancer drugs. Like I said earlier which you twisted, it's the science that has to be judged here. In a bio like, say, CELG, that isn't so important. CELG has got a dozen irons in the fire and even I have a fair handle on their science. As I said earlier ASTX science has tremendous leverage. One has to appreciate the profound function of hsp90 in all eukaryotes. Whenever you're dealing with something of Archaen origination you know that a breakthrough will be great. I was trying to explicitly respond to your ambiguous question.